. 1976 Jun;69(3):18P-19P.

Proceedings: Binding of 5 alpha-dihydrotestosterone in human prostatic cancer; examination by agar gel electrophoresis

M Nijs et al. J Endocrinol. 1976 Jun.

. 1976 Jun;69(3):18P-19P.

No abstract available

Similar articles

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T, Hashimoto Y, Takahashi K. Nishiyama T, et al. Clin Cancer Res. 2004 Nov 1;10(21):7121-6. doi: 10.1158/1078-0432.CCR-04-0913. Clin Cancer Res. 2004. PMID: 15534082
Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Nishiyama T, et al. J Urol. 2006 Oct;176(4 Pt 1):1387-91. doi: 10.1016/j.juro.2006.06.066. J Urol. 2006. PMID: 16952639
Re: Back to future-the role of complementary medicine in urology.
Pitts WR Jr. Pitts WR Jr. J Urol. 2000 Aug;164(2):461-2. J Urol. 2000. PMID: 10893622 No abstract available.
Androgen receptor assays in advanced prostatic cancer.
Buttyan R, Olsson CA. Buttyan R, et al. Urol Clin North Am. 1984 May;11(2):311-7. Urol Clin North Am. 1984. PMID: 6375068 Review.
Total androgen suppression in the management of prostatic cancer. A critical review.
Schroeder FH. Schroeder FH. Prog Clin Biol Res. 1985;185A:307-17. Prog Clin Biol Res. 1985. PMID: 3898133 Review. No abstract available.

Steroid receptors in human prostatic cancer a preliminary evaluation.
de Voogt HJ, Dingjan P. de Voogt HJ, et al. Urol Res. 1978;6(3):151-8. doi: 10.1007/BF00261316. Urol Res. 1978. PMID: 81556
Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues.
Menon M, Tananis CE, Hicks LL, Hawkins EF, McLoughlin MG, Walsh PC. Menon M, et al. J Clin Invest. 1978 Jan;61(1):150-62. doi: 10.1172/JCI108913. J Clin Invest. 1978. PMID: 73547 Free PMC article.